Blog

Resmetirom: A pioneering NASH clinical program

Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…

CertaraAugust 23, 2024

On-Demand Webinar

Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization

The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…

CertaraAugust 19, 2024

Case Study

Medicines that matter: Biohaven’s Nurtec™ drug development journey

In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved…

CertaraAugust 15, 2024

Conference

DIA Japan 2026

–

CertaraJuly 29, 2024

Publication

Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion (Zalophus californianus) and Pacific harbor seal (Phoca vitulina richardii)

Explore how both pinniped species show long meloxicam half‑lives, suggesting dosing interval reconsideration, modelled using…

CertaraJuly 14, 2024

Publication

Effect of Nutrition on Drug-Induced Liver Injury: Insights from a High-Fat Diet Mouse Model

Discover how high‑fat diet reduces acetaminophen liver injury and increases clearance in mice, analysed using…

CertaraJuly 12, 2024

Publication

Comparative pharmacokinetics of phenylbutazone in healthy young-adult and geriatric horses

See how young and geriatric horses show similar phenylbutazone PK profiles, indicating no dose adjustment…

CertaraJune 28, 2024

Publication

Ziprasidone population pharmacokinetics and co‑medication effects in Chinese patients

Learn how lorazepam and valproate significantly affect ziprasidone clearance; PopPK modelling supports personalized dosing using…

CertaraJune 25, 2024

Publication

Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants.

Find out how gestational and postnatal age drive fluconazole PK variability; PopPK modelling supports tailored…

CertaraJune 8, 2024

On-Demand Webinar